Healthcare company Northwestern Medicine on Thursday published in the Journal of the American Medical Association (JAMA) the positive outcomes in the first 30 consecutive COVID-19 patients who underwent a lung transplant in Chicago.
The outcomes for the company's COVID-19 lung transplant patients are validated by a concurrent paper in New England Journal of Medicine (NEJM). Dr Ankit Bharat, the company's chief of thoracic surgery, reportedly performed the COVID-19 lung transplant.
Among the 102 consecutive lung transplant recipients from 21 January 2020 to 30 September 2021, about 30 patients were transplanted due to COVID-19 and 72 patients were transplanted due to chronic end-stage lung disease including cystic fibrosis, pulmonary hypertension, idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease, according to the company.
In June 2020, the company's surgeons performed the first lung transplant on a COVID-19 patient in the US. To date, 40 COVID-19 patients have received its lung transplants. For COVID-19 patients with irrecoverable lung damage, transplantation is the only option for survival.
Sionna Therapeutics doses first healthy subject in SION-109 phase one clinical trial
Arcturus Therapeutics granted FDA Orphan Drug Designation for ARCT-032 to treat cystic fibrosis
SpliSense completes SPL84 first-in-human, Phase one clinical trial for cystic fibrosis treatment
Positive Phase 2, Proof-of-Concept Results for VX-548 Published in New England Journal of Medicine
Inogen acquires Physio-Assist, expanding respiratory product portfolio and global presence
cystetic Medicines doses first healthy volunteer in CM001 Phase one clinical trial
First Patient Enrolled in Phase 3 Clinical Trial Evaluating ARINA-1 in Lung Transplant